Сomparative analysis of cardiac magnetic resonance imaging data in patients with hypertrophic cardiomyopathy and Anderson-Fabry disease
https://doi.org/10.15829/1728-8800-2025-4677
EDN: OFSBJF
Abstract
Aim. Cardiac involvement in Anderson-Fabry disease (AFD) is often characterized by left ventricular hypertrophy (LVH), which can be mistaken for hypertrophic cardiomyopathy (HCM). The aim was to analyze and compare morphological and functional cardiac changes using multiparametric magnetic resonance imaging (MRI) in patients with AFD, HCM, and healthy volunteers.
Material and methods. The study included 131 patients with HCM, 42 patients with AFD, and 18 healthy volunteers. Multiparametric cardiac MRI was performed using a 3T scanner.
Results. LVH was detected in 55% of patients with AFD. Signs of myocardial fibrosis were more common in HCM than in AFD+LVH (86% vs 35%, p<0,05). Native T1 and T2 mapping and extracellular volume fraction values were higher in the HCM group than in the AFD+LVH group as follows: 1269,4±52,7 vs 1144,5±30,6 ms, 41,6±3,9 vs 40,0±1,4 ms, 0,33±0,06 vs 0,27±0,02 ms, respectively (p<0,05). Native T1 mapping values in AFD patients without LVH were significantly lower than in healthy volunteers as follows: 1124,6±45,0 vs 1207,7±40,0 ms, respectively (p<0,05).
Conclusion. Native T1 mapping values in AFD, regardless of LVH, are lower than those in patients with HCM and healthy volunteers and can be used in the early diagnosis of myocardial involvement in AFD.
About the Authors
E. V. GagarinaРоссия
Lomonosovsky Avenue, 27, bld. 10, Moscow, 119234,
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
E. A. Mershina
Россия
Lomonosovsky Avenue, 27, bld. 10, Moscow, 119234
R. P. Myasnikov
Россия
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
А. S. Moiseev
Россия
Trubetskaya str., 8, bld. 2, Moscow, 119048
O. V. Kulikova
Россия
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
M. M. Kudryavtseva
Россия
Petroverigsky Lane, 10, bld. 3, Moscow, 101990
S. F. Ageeva
Россия
Lomonosovsky Avenue, 27, bld. 10, Moscow, 119234
V. E. Sinitsyn
Россия
Lomonosovsky Avenue, 27, bld. 10, Moscow, 119234
References
1. Pieroni M, Moon JC, Arbustini E, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Col Cardiol. 2021;77:922-36. doi:10.1016/j.jacc.2020.12.024.
2. Tao E, Moiseev A, Novikov P, et al. Efficacy of family screening in Fabry disease in the Russian population. Clinical Pharmacology and Therapy. 2020;29(2):34-9. (In Russ.) doi:10.32756/0869-5490-2020-2-34-39.
3. Germain DP, Brand E, Burlina A, et al. Phenotypic characteristics of the p.Asn215Ser(p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genom Med. 2018;6:492-503. doi:10.1002/mgg3.389.
4. Azevedo O, Gal A, Faria R, et al. Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype. Mol Genet Metab. 2020;129:150-60. doi:10.1016/j.ymgme.2019.07.012.
5. Kharlap MS, Myasnikov RP, Pavlunina TО, et al. Cardiac phenotype of Fabry Disease. Russian Journal of Cardiology. 2018;(7):80-3. (In Russ.) doi:10.15829/1560-4071-2018-7-80-83.
6. Krämer J, Niemann M, Störk S, et al. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114(6):895-900. doi:10.1016/j.amjcard.2014.06.019.
7. Smirnova OYa, Vashakmadze ND, Karaseva MS, et al. Modern Approach to Fabry Disease Diagnosis and Management in Children. Current Pediatrics. 2024;23(1):6-12. (In Russ.). doi:10.15690/vsp.v23i1.2652.
8. Moiseev SV, Privalova EV, Rameev VV, et al. Unexplained left ventricular hypertrophy. Clinical Pharmacology and Therapy 2019;28(2):77-83. (In Russ.) doi:10.32756/0869-5490-2019-2-77-83.
9. Bokeria lA, Shlyakhto EV, Gabrusenko SA, et al. 2025 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2025;30(5):6387. (In Russ.) doi:10.15829/1560-4071-2025-6387.
10. Mershina EA, Ryzhkova EV, Lisitskaya MV, et al. Native T1- and T2-mapping of myocardial relaxation times in cardiovascular magnetic resonance: clinical applications. Siberian Journal of Clinical and Experimental Medicine. 2023;38(3):49-57. (In Russ.) doi:10.29001/2073-8552-2023-39-3-49-57.
11. Chen W, Doeblin P, Al-Tabatabaee S, et al. Synthetic Extracellular Volume in Cardiac Magnetic Resonance Without Blood Sampling: a Reliable Tool to Replace Conventional Extracellular Volume. Circ Cardiovasc Imaging. 2022;15(4):e013745. doi:10.1161/CIRCIMAGING.121.013745.
12. Gagarina EV, Mershina EA, Chumakova OS, et al. Comparison of cardiac morphological and functional changes according to magnetic resonance imaging with the genetic testing data in patients with hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2024;29(11):6113. (In Russ.) doi:10.15829/1560-4071-2024-6113.
Review
For citations:
Gagarina E.V., Mershina E.A., Myasnikov R.P., Moiseev А.S., Kulikova O.V., Kudryavtseva M.M., Ageeva S.F., Sinitsyn V.E. Сomparative analysis of cardiac magnetic resonance imaging data in patients with hypertrophic cardiomyopathy and Anderson-Fabry disease. Cardiovascular Therapy and Prevention. 2025;24(12):4677. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4677. EDN: OFSBJF
JATS XML

















































